Continuous erythropoietin receptor activator: all 70 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.CompletedNCT03552393Phase 2Results posted
• A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or DialysisCompletedNCT01519947Phase 4Results posted
• A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal AnemiaCompletedNCT01342640Phase 4Results posted
• A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)CompletedNCT01194154Phase 2Results posted
• A Study of Monthly Subcutaneous or Intravenous Mircera in Dialysis Patients With Chronic Renal AnaemiaCompletedNCT01156363Phase 4Results posted
• A Study for Monthly Methoxy Polyethylene Glycol-Epoetin Beta Treatment in Patients With Chronic Renal AnaemiaTerminatedNCT01066000Phase 4Results posted
• A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on DialysisCompletedNCT00922116Phase 4Results posted
• A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal AnemiaCompletedNCT00882713Phase 3Results posted
• A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal AnemiaCompletedNCT00773968Phase 3Results posted
• A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.CompletedNCT00737711Phase 4Results posted
• A Study of Monthly Subcutaneous (SC) Mircera for Maintenance Treatment of Participants With Chronic Kidney Disease on Peritoneal DialysisCompletedNCT00737477Phase 3Results posted
• A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.CompletedNCT00737464Phase 4Results posted
• Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on HemodialysisCompletedNCT00717366Phase 2Results posted
• A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal AnemiaCompletedNCT00699348Phase 3Results posted
• A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal AnemiaCompletedNCT00661505Phase 3Results posted
• A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.CompletedNCT00661388Phase 3Results posted
• A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on DialysisCompletedNCT00660023Phase 3Results posted
• STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis PatientsCompletedNCT00642850Phase 3Results posted
• A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal AnemiaCompletedNCT00642668Phase 4Results posted
• A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.CompletedNCT00642304Phase 3Results posted
• A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.CompletedNCT00605345Phase 3Results posted
• A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal AnemiaCompletedNCT00605293Phase 3Results posted
• A Study of Subcutaneous C.E.R.A. for the Treatment of Anemia in Pre-Dialysis Patients.CompletedNCT00576628Phase 3Results posted
• A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.CompletedNCT00576303Phase 3Results posted
• A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.CompletedNCT00560404Phase 3Results posted
• A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on DialysisCompletedNCT00559637Phase 3Results posted
• A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on DialysisCompletedNCT00559273Phase 3Results posted
• A Study of Mircera for the Maintenance Treatment of Participants With Chronic Renal AnemiaCompletedNCT00550680Phase 3Results posted
• A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients.CompletedNCT00546481Phase 3Results posted
• MIRACLE Study: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Participants With Chronic Renal AnemiaCompletedNCT00545571Phase 3Results posted
• Efficacy, Safety and Tolerability Study of Subcutaneous C.E.R.A. in Pre-Dialysis Participants With Chronic Renal AnemiaTerminatedNCT00517881Phase 3Results posted
• LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.CompletedNCT00517413Phase 3Results posted
• A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Participants With Chronic Kidney Disease.TerminatedNCT00462384Phase 3Results posted
• A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.TerminatedNCT00454246Phase 3Results posted
• A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.CompletedNCT00442702Phase 3Results posted
• A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.TerminatedNCT00442416Phase 3Results posted
• A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.TerminatedNCT00422513Phase 3Results posted
• A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.CompletedNCT00413894Phase 3Results posted
• A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis PatientsCompletedNCT00394953Phase 3Results posted
• A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.CompletedNCT00364832Phase 2Results posted
• A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal AnemiaCompletedNCT00090753Phase 3Results posted
• A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.CompletedNCT00077766Phase 3Results posted
• A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.CompletedNCT00077623Phase 3Results posted
• A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis PatientsCompletedNCT00077610Phase 3Results posted
• A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.CompletedNCT00048048Phase 2Results posted
• A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal AnemiaCompletedNCT00048035Phase 2Results posted
• Frequent Dosing of CERA Improves Nutrition and Inflammation in Hemodialysis PatientsCompletedNCT02232113Phase 4
• Comparison Among Erythropoietin Stimulating AgentsCompletedNCT02049346Phase 4
• Phase IV Study to Evaluate the Efficacy and Safety of Mircera in PDStatus unknownNCT01807481Phase 4
• A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic NephropathyCompletedNCT01191983Phase 4
• Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial InfarctionCompletedNCT01093820Phase 2
• A Study of Mircera in Renal Anemia Among Filipino Chronic Kidney Disease PatientsCompletedNCT00922610Phase 4
• A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.CompletedNCT00773331Phase 3
• A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.CompletedNCT00717821Phase 3
• A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.TerminatedNCT00680563Phase 3
• A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on DialysisCompletedNCT00642967Phase 3
• A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney TransplantTerminatedNCT00576602Phase 4
• A Study of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.WithdrawnNCT00560547Phase 3
• Clinical Study of R744 to Predialysis Patients( Phase III, Comparative Study in Comparison With Epoetin Beta)CompletedNCT00492427Phase 3
• Clinical Study of R744 to Hemodialysis PatientsCompletedNCT00491868Phase 3
• A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.CompletedNCT00442793Phase 3
• Switch and Maintenance Study of Intravenous Injections of R744 to Hemodialysis Patients (Phase Ⅲ Study)CompletedNCT00433888Phase 3
• Clinical Study of R744 to Peritoneal Dialysis PatientsCompletedNCT00433849Phase 3
• Correction Study of R744 in Renal Anemia Patients on HemodialysisCompletedNCT00433693Phase 3
• Clinical Study of R744 to Predialysis PatientsCompletedNCT00433615Phase 3
• A Study of Mircera in Anemic Patients With Multiple MyelomaCompletedNCT00360347Phase 1/2
• A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.CompletedNCT00327535Phase 2
• A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis PatientsCompletedNCT00081484Phase 3
• A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on DialysisCompletedNCT00081471Phase 3
• A Study of Mircera for the Treatment of Anemia in Dialysis PatientsCompletedNCT00077597Phase 3

← Continuous erythropoietin receptor activator overview